Solid Biosciences Inc. (SLDB)
$
3.26
+0.22 (6.75%)
Key metrics
Financial statements
Free cash flow per share
-2.6289
Market cap
252.7 Million
Price to sales ratio
0
Debt to equity
0.0802
Current ratio
10.8902
Income quality
0.7637
Average inventory
0
ROE
-0.7055
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Solid Biosciences Inc. is focused on developing therapies for Duchenne muscular dystrophy within the United States. The company's flagship product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at enhancing functional dystrophin protein expression in patients' muscles. In addition to SGT-001, the company is also advancing SGT-003, an next-generation gene transfer candidate targeting Duchenne muscular dystrophy. The firm is engaged in the development of innovative platform technologies, notably dual gene expression, which allows the packaging of multiple transgenes into a single vector, along with the creation of novel capsids. The gross profit ratio is 0.00 reflecting the efficiency of the company's production and sales operations. Furthermore, the company recorded an operating income of -$129,728,000.00 showcasing its earnings from core operations. The EBITDA ratio is 0.00 highlighting the company's operational efficiency, while the operating income ratio is 0.00 indicating the company's operational profitability margin. The operating expenses amount to $129,728,000.00 which encompass various operational costs incurred in pursuing its objectives. In the context of investment, the stock is affordable at $3.26 making it an attractive option for budget-conscious investors. The stock also has a low average trading volume of 1,493,927.00 suggesting lower market activity and potentially less volatility. With a market capitalization of $252,700,204.00 the company is categorized as a small-cap player, signifying its position in the broader market. It is a key player in the Biotechnology industry, making significant contributions to the overall market landscape. Additionally, it belongs to the Healthcare sector, where it is actively driving innovation and growth, indicating its commitment to advancing therapeutic solutions for rare diseases and enhancing patient care.
Is Solid Biosciences Inc. (SLDB) a good investment?
Investing in Solid Biosciences Inc. (SLDB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Solid Biosciences Inc. (SLDB)'s stock forecast?
Analysts predict Solid Biosciences Inc. stock to fluctuate between $2.41 (low) and $10.37 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Solid Biosciences Inc.'s market capitalization?
As of 2025-05-28, Solid Biosciences Inc.'s market cap is $252,700,204, based on 77,515,400 outstanding shares.
How does Solid Biosciences Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Solid Biosciences Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Solid Biosciences Inc. (SLDB) stock?
To buy Solid Biosciences Inc. (SLDB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SLDB. Place an order (Market, Limit, etc.).
What is the best time to invest in Solid Biosciences Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Solid Biosciences Inc. stock ever split?
Solid Biosciences Inc.'s last stock split was 1:15 on 2022-10-28.
How did Solid Biosciences Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3.06 | Growth: -36.65%.
Where can I find Solid Biosciences Inc.'s investor relations reports?
Visit https://www.solidbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Solid Biosciences Inc.?
You can explore historical data from here
What is the all-time high and low for Solid Biosciences Inc. stock?
All-time high: $173.70 (2021-02-24) | All-time low: $1.81 (2023-10-30).
What are the key trends affecting Solid Biosciences Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich's ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects.
marketbeat.com
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease.
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
globenewswire.com
- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways -
marketbeat.com
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
benzinga.com
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
globenewswire.com
— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants by Q4 2025 —— In mid-2025, Company plans to request an FDA meeting to discuss potential accelerated approval pathway for SGT-003 —— Company to hold a conference call today at 8:00 AM ET —
See all news
